{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "import xml.etree.ElementTree as ET\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.tokenize import word_tokenize\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_xml(path):\n",
    "    tree = ET.parse(path)\n",
    "    return tree"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\\ndef change_sentece(charOffset,sent,drug,bias = 0):\\n    #durg_length = 5\\n    posCollect = charOffset.split(\\';\\')\\n    anssent = sent\\n    for pos in posCollect:\\n        white_space = \"\"\\n        pos_begin,pos_end = pos.split(\\'-\\')\\n        pos_begin = int(pos_begin) + bias\\n        pos_end = int(pos_end) + bias\\n        item_length = pos_end - pos_begin + 1\\n        if item_length < 5:\\n            bias += 5 - item_length\\n        while(item_length > 5):\\n            white_space += \" \"\\n            item_length -= 1\\n        anssent =  anssent[0:pos_begin] + drug + white_space+anssent[pos_end+1:]\\n        drug = \"\"\\n    return anssent,bias\\n'"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "'''\n",
    "def change_sentece(charOffset,sent,drug,bias = 0):\n",
    "    #durg_length = 5\n",
    "    posCollect = charOffset.split(';')\n",
    "    anssent = sent\n",
    "    for pos in posCollect:\n",
    "        white_space = \"\"\n",
    "        pos_begin,pos_end = pos.split('-')\n",
    "        pos_begin = int(pos_begin) + bias\n",
    "        pos_end = int(pos_end) + bias\n",
    "        item_length = pos_end - pos_begin + 1\n",
    "        if item_length < 5:\n",
    "            bias += 5 - item_length\n",
    "        while(item_length > 5):\n",
    "            white_space += \" \"\n",
    "            item_length -= 1\n",
    "        anssent =  anssent[0:pos_begin] + drug + white_space+anssent[pos_end+1:]\n",
    "        drug = \"\"\n",
    "    return anssent,bias\n",
    "'''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Hello Worlds afew\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'Hello AAAAAA afew'"
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "change_sentece(\"6-10\",\"Hello Worlds afew\",'A')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "def change_sentece(charOffset,sent,char_drug):\n",
    "    flag = False\n",
    "    posCollect = charOffset.split(';')\n",
    "    anssent = sent\n",
    "    for pos in posCollect:\n",
    "        drug = \"\"\n",
    "        pos_begin,pos_end = pos.split('-')\n",
    "        pos_begin = int(pos_begin) \n",
    "        pos_end = int(pos_end) \n",
    "        for i in range(pos_begin,pos_end + 1):drug+= char_drug\n",
    "        for i in range(pos_begin - 1,-1,-1):\n",
    "            \n",
    "            if(anssent[i] == \" \"):break\n",
    "            flag = True\n",
    "            anssent =  anssent[0:i] + char_drug +anssent[i+1:]\n",
    "        for i in range(pos_end + 1,len(anssent)):\n",
    "            #print(i)\n",
    "            if(anssent[i] == \" \"):break\n",
    "            flag = True\n",
    "            anssent =  anssent[0:i] + char_drug +anssent[i+1:]\n",
    "        if flag:print(sent)\n",
    "        anssent =  anssent[0:pos_begin] + drug +anssent[pos_end+1:]\n",
    "    return anssent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [],
   "source": [
    "def A_to_drug0(word,charr):\n",
    "    if(len(word) == 0):return word\n",
    "    for alpha in word:\n",
    "        if alpha!= charr:\n",
    "            return word\n",
    "    return \"drug\" + charr\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [],
   "source": [
    "def nltk_and_drugA(sentence):\n",
    "    \n",
    "    nltk_text = word_tokenize(sentence)\n",
    "    words = nltk_text\n",
    "    #words = [word for word in nltk_text if word.isalpha()]\n",
    "    after_replace = []\n",
    "    for word in words:\n",
    "        word = A_to_drug0(word,'A')\n",
    "        word = A_to_drug0(word,'B')\n",
    "        word = A_to_drug0(word,'N')\n",
    "        after_replace.append(word)\n",
    "        #print(word)\n",
    "    #word_lower = [word.lower() for word in after_replace]\n",
    "    #word_no_stop = [word for word in word_lower if word not in stopwords.words('english')]\n",
    "    \n",
    "    #return \" \".join(word_lower)\n",
    "    #return \" \".join(word_no_stop)  \n",
    "    return \" \".join(after_replace)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_nltk(sentence):\n",
    "    \n",
    "    nltk_text = word_tokenize(sentence)\n",
    "    word_lower = [word.lower() for word in nltk_text]\n",
    "    \n",
    "    #return \" \".join(word_lower)\n",
    "    return \" \".join(word_lower)    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_dict(root,idd):\n",
    "    fout = open(\"test7.txt\",\"a\")\n",
    "    #fout = open(\"origin.txt\",\"a\")\n",
    "    for sentence in (root):\n",
    "        entity_pos = {}\n",
    "        entity_ids = []\n",
    "        mysentece = sentence.attrib[\"text\"]\n",
    "        for entity in sentence:\n",
    "            if entity.tag == \"entity\":\n",
    "                entity_pos[entity.attrib[\"id\"]] = entity.attrib[\"charOffset\"]\n",
    "                entity_ids.append(entity.attrib[\"id\"])\n",
    "        for pair in sentence:\n",
    "            if pair.tag == \"pair\":\n",
    "                new_sent = mysentece\n",
    "                for entity_id in entity_ids:\n",
    "                    if entity_id == pair.attrib[\"e1\"] :\n",
    "                        new_sent =change_sentece(entity_pos[entity_id],new_sent,\"A\")\n",
    "                    elif entity_id == pair.attrib[\"e2\"]:\n",
    "                        new_sent =change_sentece(entity_pos[entity_id],new_sent,\"B\") \n",
    "                    else:\n",
    "                        new_sent =change_sentece(entity_pos[entity_id],new_sent,\"N\")\n",
    "                new_sent = nltk_and_drugA(new_sent)\n",
    "                typee = pair.attrib[\"ddi\"]\n",
    "                if pair.get(\"type\"):\n",
    "                    typee = pair.attrib[\"type\"]\n",
    "               # print(new_sent)\n",
    "               # print(typee)\n",
    "                #fout.write(str(idd)+\"\\n\")\n",
    "                fout.write(new_sent + \"\\n\")\n",
    "                fout.write(typee +\"\\n\")\n",
    "                idd += 1\n",
    "    return idd\n",
    "                \n",
    "                "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. \n",
      "In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "Weekly intramuscular NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN injections (0.2-0.5 mg/kg body weight), in combination with daily administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). \n",
      "After 21 weeks of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA treatment, all BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA treatment, all BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB animals displayed parkinsonian symptoms, whereas none of the NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA treatment, all NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA treatment, all NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN animals displayed parkinsonian symptoms, whereas none of the BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA treatment, all NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA treatment, all NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN animals displayed parkinsonian symptoms, whereas none of the NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN treatment, all AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN treatment, all AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA animals displayed parkinsonian symptoms, whereas none of the BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN treatment, all AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN treatment, all AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA animals displayed parkinsonian symptoms, whereas none of the NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN treatment, all NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "After 21 weeks of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN treatment, all NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN animals displayed parkinsonian symptoms, whereas none of the AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA ethynyl] pyridine-treated monkeys were significantly affected. \n",
      "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. \n",
      "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. \n",
      "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. \n",
      "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. \n",
      "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. \n",
      "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. \n",
      "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. \n",
      "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. \n",
      "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. \n",
      "The AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. \n",
      "In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. \n",
      "In AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. \n",
      "In AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB ethynyl] pyridine-treated monkeys. \n",
      "In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. \n",
      "In AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. \n",
      "In AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN ethynyl] pyridine-treated monkeys. \n",
      "In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. \n",
      "In NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. \n",
      "In NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA ethynyl] pyridine-treated monkeys. \n",
      "Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. \n",
      "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of AAAAAAAAAAAAAAAAAAAAA CYP3A4 inhibition on clinical pharmacokinetics of BBBBBBBBBBBB (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of AAAAAAAAAAAAAAAAAAAAA CYP3A4 inhibition on clinical pharmacokinetics of BBBBBBBBBBBB NNNNNNNNN an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of AAAAAAAAAAAAAAAAAAAAA CYP3A4 inhibition on clinical pharmacokinetics of NNNNNNNNNNNN (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of AAAAAAAAAAAAAAAAAAAAA CYP3A4 inhibition on clinical pharmacokinetics of NNNNNNNNNNNN BBBBBBBBB an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of AAAAAAAAAAAAAAAAAAAAA CYP3A4 inhibition on clinical pharmacokinetics of NNNNNNNNNNNN (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of AAAAAAAAAAAAAAAAAAAAA CYP3A4 inhibition on clinical pharmacokinetics of NNNNNNNNNNNN NNNNNNNNN an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of NNNNNNNNNNNNNNNNNNNNN CYP3A4 inhibition on clinical pharmacokinetics of AAAAAAAAAAAA (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of NNNNNNNNNNNNNNNNNNNNN CYP3A4 inhibition on clinical pharmacokinetics of AAAAAAAAAAAA BBBBBBBBB an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of NNNNNNNNNNNNNNNNNNNNN CYP3A4 inhibition on clinical pharmacokinetics of AAAAAAAAAAAA (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of NNNNNNNNNNNNNNNNNNNNN CYP3A4 inhibition on clinical pharmacokinetics of AAAAAAAAAAAA NNNNNNNNN an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of NNNNNNNNNNNNNNNNNNNNN CYP3A4 inhibition on clinical pharmacokinetics of NNNNNNNNNNNN (LBH589), an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "Effect of NNNNNNNNNNNNNNNNNNNNN CYP3A4 inhibition on clinical pharmacokinetics of NNNNNNNNNNNN AAAAAAAAA an orally active histone deacetylase inhibitor.\r\n",
      "\n",
      "This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.\n",
      "This study evaluated the effect of a potent CYP3A inhibitor, AAAAAAAAAAAAA on the pharmacokinetics and safety of panobinostat.\n",
      "On day 8, a single AAAAAAAAAAAA dose was co-administered with ketoconazole. \n",
      "In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively. \n",
      "In the presence of AAAAAAAAAAAAA there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively. \n",
      "Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of AAAAAAAAAAAA was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary.\n",
      "Being AAAAAAAAAAAA and lomefloxacin BBBBBBBBBBBBBBBB the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin BBBBBBBBBBBBBBBB the interaction study of was carried out with NNNNNNNNNNN gelusil, erythromycin and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin BBBBBBBBBBBBBBBB the interaction study of was carried out with NNNNNNNNNNN NNNNNNNN NNNNNNNNNNNN and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with BBBBBBBBBBB gelusil, erythromycin and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with BBBBBBBBBBB NNNNNNNN NNNNNNNNNNNN and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN gelusil, erythromycin and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN BBBBBBBB NNNNNNNNNNNN and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN gelusil, erythromycin and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN NNNNNNNN BBBBBBBBBBBB and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN gelusil, erythromycin and multi minerals. \n",
      "Being AAAAAAAAAAAA and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN NNNNNNNN NNNNNNNNNNNN and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with BBBBBBBBBBB gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with BBBBBBBBBBB NNNNNNNN NNNNNNNNNNNN and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with NNNNNNNNNNN gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with NNNNNNNNNNN BBBBBBBB NNNNNNNNNNNN and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with NNNNNNNNNNN gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with NNNNNNNNNNN NNNNNNNN BBBBBBBBBBBB and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with NNNNNNNNNNN gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin AAAAAAAAAAAAAAAA the interaction study of was carried out with NNNNNNNNNNN NNNNNNNN NNNNNNNNNNNN and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with AAAAAAAAAAA gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with AAAAAAAAAAA BBBBBBBB NNNNNNNNNNNN and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with AAAAAAAAAAA gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with AAAAAAAAAAA NNNNNNNN BBBBBBBBBBBB and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with AAAAAAAAAAA gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with AAAAAAAAAAA NNNNNNNN NNNNNNNNNNNN and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN AAAAAAAA BBBBBBBBBBBB and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN AAAAAAAA NNNNNNNNNNNN and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN gelusil, erythromycin and multi minerals. \n",
      "Being NNNNNNNNNNNN and lomefloxacin NNNNNNNNNNNNNNNN the interaction study of was carried out with NNNNNNNNNNN NNNNNNNN AAAAAAAAAAAA and multi minerals. \n",
      "Exposure to oral AAAAAAAAAA is unaffected by BBBBBBBBBBBB but greatly increased by ticlopidine.\r\n",
      "\n",
      "Exposure to oral AAAAAAAAAA is unaffected by NNNNNNNNNNNN but greatly increased by ticlopidine.\r\n",
      "\n",
      "Exposure to oral NNNNNNNNNN is unaffected by AAAAAAAAAAAA but greatly increased by ticlopidine.\r\n",
      "\n",
      "This study examined drug-drug interactions of oral AAAAAAAAAA with the cytochrome P450 (CYP) 2B6 inhibitor BBBBBBBBBBB and the CYP3A inhibitor itraconazole. \n",
      "This study examined drug-drug interactions of oral AAAAAAAAAA with the cytochrome P450 (CYP) 2B6 inhibitor NNNNNNNNNNN and the CYP3A inhibitor itraconazole. \n",
      "This study examined drug-drug interactions of oral NNNNNNNNNN with the cytochrome P450 (CYP) 2B6 inhibitor AAAAAAAAAAA and the CYP3A inhibitor itraconazole. \n",
      "AAAAAAAAAAA treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral BBBBBBBB by 2.4-fold, whereas NNNNNNNNNNNN treatment did not increase the exposure to S-ketamine. \n",
      "AAAAAAAAAAA treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral NNNNNNNN by 2.4-fold, whereas BBBBBBBBBBBB treatment did not increase the exposure to S-ketamine. \n",
      "AAAAAAAAAAA treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral NNNNNNNN by 2.4-fold, whereas NNNNNNNNNNNN treatment did not increase the exposure to S-ketamine. \n",
      "NNNNNNNNNNN treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral AAAAAAAA by 2.4-fold, whereas BBBBBBBBBBBB treatment did not increase the exposure to S-ketamine. \n",
      "NNNNNNNNNNN treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral AAAAAAAA by 2.4-fold, whereas NNNNNNNNNNNN treatment did not increase the exposure to S-ketamine. \n",
      "NNNNNNNNNNN treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral NNNNNNNN by 2.4-fold, whereas AAAAAAAAAAAA treatment did not increase the exposure to S-ketamine. \n",
      "The findings suggest that the dosage of AAAAAAAAAA should be reduced in patients receiving ticlopidine.\n",
      "The AAAAAAAAAAAAAAAAAAA (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. \n",
      "We also found that Bcl-2 was overexpressed in AAAAA insensitive cells, and cotreatment with BBBBB and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. \n",
      "We also found that Bcl-2 was overexpressed in AAAAA insensitive cells, and cotreatment with NNNNN and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. \n",
      "We also found that Bcl-2 was overexpressed in AAAAA insensitive cells, and cotreatment with NNNNN and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. \n",
      "We also found that Bcl-2 was overexpressed in NNNNN insensitive cells, and cotreatment with AAAAA and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. \n",
      "We also found that Bcl-2 was overexpressed in NNNNN insensitive cells, and cotreatment with AAAAA and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. \n",
      "We also found that Bcl-2 was overexpressed in NNNNN insensitive cells, and cotreatment with NNNNN and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. \n",
      "Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.\r\n",
      "\n",
      "AAAAAAAAAAAAAAAAAAAAAAA interaction and associated gastrointestinal bleeding risk in a case-control study.\r\n",
      "\n",
      "Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). \n",
      "Also AAAAAAAAAAAA which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). \n",
      "AAAAAAAA users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated BBBBBBBBBBB fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated BBBBBBBBBBB NNNNNNNNNNN paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated BBBBBBBBBBB NNNNNNNNNNN NNNNNNNNNNN amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN BBBBBBBBBBB paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN BBBBBBBBBBB NNNNNNNNNNN amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN NNNNNNNNNNN paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN NNNNNNNNNNN BBBBBBBBBBB amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN NNNNNNNNNNN paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN NNNNNNNNNNN NNNNNNNNNNN amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN NNNNNNNNNNN paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "AAAAAAAA users who initiated NNNNNNNNNNN NNNNNNNNNNN NNNNNNNNNNN amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA BBBBBBBBBBB paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA BBBBBBBBBBB NNNNNNNNNNN amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA NNNNNNNNNNN paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA NNNNNNNNNNN BBBBBBBBBBB amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA NNNNNNNNNNN paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA NNNNNNNNNNN NNNNNNNNNNN amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA NNNNNNNNNNN paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated AAAAAAAAAAA NNNNNNNNNNN NNNNNNNNNNN amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN AAAAAAAAAAA paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN AAAAAAAAAAA BBBBBBBBBBB amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN AAAAAAAAAAA paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN AAAAAAAAAAA NNNNNNNNNNN amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN AAAAAAAAAAA paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN AAAAAAAAAAA NNNNNNNNNNN amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN NNNNNNNNNNN paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN NNNNNNNNNNN AAAAAAAAAAA amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN NNNNNNNNNNN paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN NNNNNNNNNNN AAAAAAAAAAA amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN NNNNNNNNNNN paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "NNNNNNNN users who initiated NNNNNNNNNNN NNNNNNNNNNN NNNNNNNNNNN amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. \n",
      "The incubations were performed in the absence and presence of the non-specific CYP inhibitor, AAAAAAAAAAAAAAAAAAAA (ABT) and isoform-specific inhibitors. \n",
      "AAA decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN \n",
      "With respect to toxicity, the order of CYP inhibitor effectiveness was AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA \n",
      "To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of AAAAAAAAAAAAAAAAAAAAAAAA (AAV2).\n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including BBBBBBBBBBBB hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including BBBBBBBBBBBB NNNNNNNNNNNNNNNNN heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including BBBBBBBBBBBB NNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNN or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN BBBBBBBBBBBBBBBBB heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN BBBBBBBBBBBBBBBBB NNNNNNNNNNNNNNN or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN NNNNNNNNNNNNNNNNN heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN NNNNNNNNNNNNNNNNN BBBBBBBBBBBBBBB or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN NNNNNNNNNNNNNNNNN heparinase III, or chondroitin ABC lyase. \n",
      "AAAA containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN NNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNN or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including AAAAAAAAAAAA hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including AAAAAAAAAAAA BBBBBBBBBBBBBBBBB heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including AAAAAAAAAAAA BBBBBBBBBBBBBBBBB NNNNNNNNNNNNNNN or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including AAAAAAAAAAAA hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including AAAAAAAAAAAA NNNNNNNNNNNNNNNNN heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including AAAAAAAAAAAA NNNNNNNNNNNNNNNNN BBBBBBBBBBBBBBB or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including AAAAAAAAAAAA hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including AAAAAAAAAAAA NNNNNNNNNNNNNNNNN heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including AAAAAAAAAAAA NNNNNNNNNNNNNNNNN NNNNNNNNNNNNNNN or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN AAAAAAAAAAAAAAAAA heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN AAAAAAAAAAAAAAAAA BBBBBBBBBBBBBBB or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN AAAAAAAAAAAAAAAAA heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN AAAAAAAAAAAAAAAAA NNNNNNNNNNNNNNN or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN hyaluronan lyase, heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN NNNNNNNNNNNNNNNNN heparinase III, or chondroitin ABC lyase. \n",
      "NNNN containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including NNNNNNNNNNNN NNNNNNNNNNNNNNNNN AAAAAAAAAAAAAAA or chondroitin ABC lyase. \n",
      "AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. \n",
      "AAAAAAAAAAAAA retinal transduction is improved by co-injection of BBBBBBBBBBBBBB or chondroitin ABC lyase. \n",
      "AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. \n",
      "AAAAAAAAAAAAA retinal transduction is improved by co-injection of NNNNNNNNNNNNNN or chondroitin ABC lyase. \n",
      "AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. \n",
      "NNNNNNNNNNNNN retinal transduction is improved by co-injection of AAAAAAAAAAAAAA or chondroitin ABC lyase. \n",
      "EA signs were observed in all 7 patients in association with AAAAAAAA TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose BBBBBBBB was added to propofol. \n",
      "EA signs were observed in all 7 patients in association with AAAAAAAA TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose NNNNNNNN was added to propofol. \n",
      "EA signs were observed in all 7 patients in association with NNNNNNNN TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose AAAAAAAA was added to propofol. \n",
      "Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer. \n",
      "AAAAAAAAAA an estrogen antagonist, is the standard hormone treatment for breast cancer. \n",
      "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with AAAAAAAAA for breast cancer, especially BBBBBBBBBBBBBBBBBBBB such as NNNNNNNNNN and fluoxetine. \n",
      "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with AAAAAAAAA for breast cancer, especially NNNNNNNNNNNNNNNNNNNN such as BBBBBBBBBB and fluoxetine. \n",
      "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with AAAAAAAAA for breast cancer, especially NNNNNNNNNNNNNNNNNNNN such as NNNNNNNNNN and fluoxetine. \n",
      "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with NNNNNNNNN for breast cancer, especially AAAAAAAAAAAAAAAAAAAA such as BBBBBBBBBB and fluoxetine. \n",
      "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with NNNNNNNNN for breast cancer, especially AAAAAAAAAAAAAAAAAAAA such as NNNNNNNNNN and fluoxetine. \n",
      "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with NNNNNNNNN for breast cancer, especially NNNNNNNNNNNNNNNNNNNN such as AAAAAAAAAA and fluoxetine. \n",
      "If in certain cases, an AAAAAAAAAAAAAA is considered necessary, it may be advisable to replace BBBBBBBBB with anastrozole.\n",
      "If in certain cases, an AAAAAAAAAAAAAA is considered necessary, it may be advisable to replace NNNNNNNNN with anastrozole.\n",
      "If in certain cases, an NNNNNNNNNNNNNN is considered necessary, it may be advisable to replace AAAAAAAAA with anastrozole.\n",
      "AAAAAAAAAAA locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.\r\n",
      "\n",
      "In female rats, neonatal AAAAAAAAAA treatment enhanced BBBBBBBBBBB locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. \n",
      "In female rats, neonatal AAAAAAAAAA treatment enhanced BBBBBBBBBBB locomotor sensitization compared with NNNNNNNNNNNNNNN controls sensitized to amphetamine. \n",
      "In female rats, neonatal AAAAAAAAAA treatment enhanced NNNNNNNNNNN locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. \n",
      "In female rats, neonatal AAAAAAAAAA treatment enhanced NNNNNNNNNNN locomotor sensitization compared with BBBBBBBBBBBBBBB controls sensitized to amphetamine. \n",
      "In female rats, neonatal AAAAAAAAAA treatment enhanced NNNNNNNNNNN locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. \n",
      "In female rats, neonatal AAAAAAAAAA treatment enhanced NNNNNNNNNNN locomotor sensitization compared with NNNNNNNNNNNNNNN controls sensitized to amphetamine. \n",
      "In female rats, neonatal NNNNNNNNNN treatment enhanced AAAAAAAAAAA locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. \n",
      "In female rats, neonatal NNNNNNNNNN treatment enhanced AAAAAAAAAAA locomotor sensitization compared with BBBBBBBBBBBBBBB controls sensitized to amphetamine. \n",
      "In female rats, neonatal NNNNNNNNNN treatment enhanced AAAAAAAAAAA locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. \n",
      "In female rats, neonatal NNNNNNNNNN treatment enhanced AAAAAAAAAAA locomotor sensitization compared with NNNNNNNNNNNNNNN controls sensitized to amphetamine. \n",
      "In female rats, neonatal NNNNNNNNNN treatment enhanced NNNNNNNNNNN locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. \n",
      "In female rats, neonatal NNNNNNNNNN treatment enhanced NNNNNNNNNNN locomotor sensitization compared with AAAAAAAAAAAAAAA controls sensitized to amphetamine. \n",
      "Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole. \n",
      "Male rats demonstrated sensitization to AAAAAAAAAAAA although this was muted compared with female rats, and were unaffected by neonatal quinpirole. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the BBBBBBBBBBBBBBBBBB context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the BBBBBBBBBBBBBBBBBB context compared with NNNNNNNNNNNNNNN controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with BBBBBBBBBBBBBBB controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with NNNNNNNNNNNNNNN controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal AAAAAAAAAA enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with NNNNNNNNNNNNNNN controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the AAAAAAAAAAAAAAAAAA context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the AAAAAAAAAAAAAAAAAA context compared with BBBBBBBBBBBBBBB controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the AAAAAAAAAAAAAAAAAA context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the AAAAAAAAAAAAAAAAAA context compared with NNNNNNNNNNNNNNN controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the AAAAAAAAAAAAAAAAAA context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the AAAAAAAAAAAAAAAAAA context compared with NNNNNNNNNNNNNNN controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with AAAAAAAAAAAAAAA controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with AAAAAAAAAAAAAAA controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "Rats treated with neonatal NNNNNNNNNN enhanced time spent in the NNNNNNNNNNNNNNNNNN context compared with NNNNNNNNNNNNNNN controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. \n",
      "In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.\r\n",
      "\n",
      "In vivo CYP3A activity is significantly lower in AAAAAAAAAAAAAAAAAAAA as compared with tacrolimus-treated renal allograft recipients.\r\n",
      "\n",
      "Systemic and apparent oral AAAAAAAAA clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). \n",
      "Systemic and apparent oral AAAAAAAAA clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in BBBBBBBBBBBBBBBBBBBB patients (n = 20) than in matched tacrolimus-treated patients (n = 20). \n",
      "Systemic and apparent oral AAAAAAAAA clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). \n",
      "Systemic and apparent oral AAAAAAAAA clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in NNNNNNNNNNNNNNNNNNNN patients (n = 20) than in matched tacrolimus-treated patients (n = 20). \n",
      "Systemic and apparent oral NNNNNNNNN clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). \n",
      "Systemic and apparent oral NNNNNNNNN clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in AAAAAAAAAAAAAAAAAAAA patients (n = 20) than in matched tacrolimus-treated patients (n = 20). \n",
      "The latter displayed AAAAAAAAA clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). \n",
      "The latter displayed AAAAAAAAA clearances similar to those in two larger cohorts of nonmatched BBBBBBBBBBBBBBBBBB patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). \n",
      "The latter displayed AAAAAAAAA clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). \n",
      "The latter displayed AAAAAAAAA clearances similar to those in two larger cohorts of nonmatched NNNNNNNNNNNNNNNNNN patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). \n",
      "The latter displayed NNNNNNNNN clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). \n",
      "The latter displayed NNNNNNNNN clearances similar to those in two larger cohorts of nonmatched AAAAAAAAAAAAAAAAAA patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). \n",
      "This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving AAAAAAAAAAAA than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. \n",
      "This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving AAAAAAAAAAAA than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. \n",
      "This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving NNNNNNNNNNNN than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. \n",
      "Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to AAAAAAAAAAAAAA (EPO) resistance. \n",
      "This study investigates the ability of AAAAAAAAAAAAAAAAAAAAAAAAAAA to sensitize cells from different origins to several chemotherapeutic agents. \n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to AAAAA cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to AAAAA cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to AAAAA cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to AAAAA cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to NNNNN cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to NNNNN cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to NNNNN cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to NNNNN cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to NNNNN cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to NNNNN cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.\n",
      "[Interaction between AAAAAAAAAAA and proton pump inhibitors].\r\n",
      "\n",
      "Contradictory results regarding the effect of AAAAAAAAAAAAAAAAAAAAAA on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature. \n",
      "AAAAAAAAAAAA has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. \n",
      "To date, there is no conclusive evidence of a clinically-relevant interaction between any of the AAAAAAAAAAAAAAAAAAAAAA and clopidogrel.\n",
      "In vitro activity of AAAAAAAAAAA combined with BBBBBBBBBB against clinical isolates of methicillin-resistant Staphylococcus aureus.\r\n",
      "\n",
      "In vitro activity of AAAAAAAAAAA combined with NNNNNNNNNN against clinical isolates of methicillin-resistant Staphylococcus aureus.\r\n",
      "\n",
      "In vitro activity of NNNNNNNNNNN combined with AAAAAAAAAA against clinical isolates of methicillin-resistant Staphylococcus aureus.\r\n",
      "\n",
      "This study aimed to evaluate the in vitro activity of AAAAAAAAAAA combined with BBBBBBBBBB against isolates of methicillin-resistant Staphylococcus aureus (MRSA). \n",
      "This study aimed to evaluate the in vitro activity of AAAAAAAAAAA combined with NNNNNNNNNN against isolates of methicillin-resistant Staphylococcus aureus (MRSA). \n",
      "This study aimed to evaluate the in vitro activity of NNNNNNNNNNN combined with AAAAAAAAAA against isolates of methicillin-resistant Staphylococcus aureus (MRSA). \n",
      "The authors report the case of an infant with confirmed congenital hypothyroidism on AAAAAAAAAAAAA who experienced a possible drug interaction with simeticone. \n",
      "Questioning revealed the child was taking AAAAAAA drops before feeds while on levothyroxine. \n",
      "AAAAAAA is the only known component in the diet that may affect absorption of both nonheme and heme iron. \n",
      "AAAAAAA is the only known component in the diet that may affect absorption of both BBBBBBB and heme BBBBB \n",
      "AAAAAAA is the only known component in the diet that may affect absorption of both nonheme and heme iron. \n",
      "AAAAAAA is the only known component in the diet that may affect absorption of both NNNNNNN and heme NNNNN \n",
      "NNNNNNN is the only known component in the diet that may affect absorption of both nonheme and heme iron. \n",
      "NNNNNNN is the only known component in the diet that may affect absorption of both AAAAAAA and heme AAAAA \n",
      "We evaluated the effects of AAAAAAA doses between 200 and 1500 mg on absorption of 5 mg BBBBBBBBBBBB (as ferrous sulfate). \n",
      "We evaluated the effects of AAAAAAA doses between 200 and 1500 mg on absorption of 5 mg NNNNNNNNNNNN (as ferrous sulfate). \n",
      "We evaluated the effects of NNNNNNN doses between 200 and 1500 mg on absorption of 5 mg AAAAAAAAAAAA (as ferrous sulfate). \n",
      "In conclusion, we demonstrated an isolated effect of AAAAAAA (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. \n",
      "In conclusion, we demonstrated an isolated effect of AAAAAAA (as chloride) on absorption of 5 mg of iron provided as BBBBBBB (as sulfate) and heme (as CRBC) BBBBB \n",
      "In conclusion, we demonstrated an isolated effect of AAAAAAA (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. \n",
      "In conclusion, we demonstrated an isolated effect of AAAAAAA (as chloride) on absorption of 5 mg of iron provided as NNNNNNN (as sulfate) and heme (as CRBC) NNNNN \n",
      "In conclusion, we demonstrated an isolated effect of NNNNNNN (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. \n",
      "In conclusion, we demonstrated an isolated effect of NNNNNNN (as chloride) on absorption of 5 mg of iron provided as AAAAAAA (as sulfate) and heme (as CRBC) AAAAA \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "When cells were exposed to AAAAAAAAA followed by sunitinib, synergism was observed. \n",
      "The molecular basis of this synergism is that the signaling pathways that were initially activated by AAAAAAAAA exposure were efficiently suppressed by the subsequent exposure to sunitinib. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only AAAAAAAAAAAAA carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only AAAAAAAAAAAAA carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only AAAAAAAAAAAAA carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only NNNNNNNNNNNNN carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only NNNNNNNNNNNNN carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Results revealed that the strains were resistant to many drugs at high levels, only NNNNNNNNNNNNN carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. \n",
      "Synergism was also noted when AAAAAAAAAAAAA was combined with BBBBBBBBBBBBB and amikacin.\n",
      "Synergism was also noted when AAAAAAAAAAAAA was combined with NNNNNNNNNNNNN and amikacin.\n",
      "Synergism was also noted when NNNNNNNNNNNNN was combined with AAAAAAAAAAAAA and amikacin.\n",
      "(ii) AAAAAAAAAAAAAAAAAA elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.\n",
      "The effects of AAAAAAAAAAAAAAAAAAAAAA BBBBBBBBB [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) \n",
      "The effects of AAAAAAAAAAAAAAAAAAAAAA NNNNNNNNN [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) \n",
      "The effects of NNNNNNNNNNNNNNNNNNNNNN AAAAAAAAA [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) \n",
      "and/or AAAAAAAAAAAAAAA BBBBBBBBBBB (100 mg/kg, p. o.), as well as that of neurotoxin NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN (MPTP) (4 x 20 mg/kg, i. p.) \n",
      "and/or AAAAAAAAAAAAAAA NNNNNNNNNNN (100 mg/kg, p. o.), as well as that of neurotoxin BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB (MPTP) (4 x 20 mg/kg, i. p.) \n",
      "and/or AAAAAAAAAAAAAAA NNNNNNNNNNN (100 mg/kg, p. o.), as well as that of neurotoxin NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN (MPTP) (4 x 20 mg/kg, i. p.) \n",
      "and/or NNNNNNNNNNNNNNN AAAAAAAAAAA (100 mg/kg, p. o.), as well as that of neurotoxin BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB (MPTP) (4 x 20 mg/kg, i. p.) \n",
      "and/or NNNNNNNNNNNNNNN AAAAAAAAAAA (100 mg/kg, p. o.), as well as that of neurotoxin NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN (MPTP) (4 x 20 mg/kg, i. p.) \n",
      "and/or NNNNNNNNNNNNNNN NNNNNNNNNNN (100 mg/kg, p. o.), as well as that of neurotoxin AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA (MPTP) (4 x 20 mg/kg, i. p.) \n",
      "The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.\r\n",
      "\n",
      "The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. \n",
      "Treatment of HEY xenograft-bearing mice with AAAAAAAAA plus BBBBBBBBBB inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, NNNNNNNNN + NNNNNNNNNN vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); \n",
      "Treatment of HEY xenograft-bearing mice with AAAAAAAAA plus NNNNNNNNNN inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, BBBBBBBBB + NNNNNNNNNN vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); \n",
      "Treatment of HEY xenograft-bearing mice with AAAAAAAAA plus NNNNNNNNNN inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, NNNNNNNNN + BBBBBBBBBB vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); \n",
      "Treatment of HEY xenograft-bearing mice with AAAAAAAAA plus NNNNNNNNNN inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, NNNNNNNNN + NNNNNNNNNN vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); \n",
      "Treatment of HEY xenograft-bearing mice with NNNNNNNNN plus AAAAAAAAAA inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, BBBBBBBBB + NNNNNNNNNN vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); \n",
      "Treatment of HEY xenograft-bearing mice with NNNNNNNNN plus AAAAAAAAAA inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, NNNNNNNNN + BBBBBBBBBB vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); \n",
      "Treatment of HEY xenograft-bearing mice with NNNNNNNNN plus AAAAAAAAAA inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, NNNNNNNNN + NNNNNNNNNN vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); \n",
      "Treatment of HEY xenograft-bearing mice with NNNNNNNNN plus NNNNNNNNNN inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, AAAAAAAAA + BBBBBBBBBB vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); \n",
      "Treatment of HEY xenograft-bearing mice with NNNNNNNNN plus NNNNNNNNNN inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, AAAAAAAAA + NNNNNNNNNN vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); \n",
      "Treatment of HEY xenograft-bearing mice with NNNNNNNNN plus NNNNNNNNNN inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, NNNNNNNNN + AAAAAAAAAA vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); \n",
      "The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). \n",
      "The siRNA knockdown of p27(Kip1) decreased AAAAAAAAAA and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). \n",
      "Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. \n",
      "Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that AAAAAAAAAAAAAAAAAA induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. \n",
      "Phase I trial of AAAAAAAAAAAA and BBBBBBB in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of AAAAAAAAAAAA and BBBBBBB in patients with relapsed multiple myeloma: evidence for NNNNNNNNNNNNNNNNNNNN interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of AAAAAAAAAAAA and NNNNNNN in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of AAAAAAAAAAAA and NNNNNNN in patients with relapsed multiple myeloma: evidence for BBBBBBBBBBBBBBBBBBBB interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of AAAAAAAAAAAA and NNNNNNN in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of AAAAAAAAAAAA and NNNNNNN in patients with relapsed multiple myeloma: evidence for NNNNNNNNNNNNNNNNNNNN interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of NNNNNNNNNNNN and AAAAAAA in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of NNNNNNNNNNNN and AAAAAAA in patients with relapsed multiple myeloma: evidence for BBBBBBBBBBBBBBBBBBBB interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of NNNNNNNNNNNN and AAAAAAA in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of NNNNNNNNNNNN and AAAAAAA in patients with relapsed multiple myeloma: evidence for NNNNNNNNNNNNNNNNNNNN interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of NNNNNNNNNNNN and NNNNNNN in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n",
      "\n",
      "Phase I trial of NNNNNNNNNNNN and NNNNNNN in patients with relapsed multiple myeloma: evidence for AAAAAAAAAAAAAAAAAAAA interaction via P-glycoprotein.\r\n",
      "\n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA BBBBBB on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA BBBBBB on the humoral immune responses of chickens to NNNNNNNNNNNNNN and AI NNNNNNNNN \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA BBBBBB on the humoral immune responses of chickens to NNNNNNNNNNNNNN and AI NNNNNNNNN \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA BBBBBB on the humoral immune responses of chickens to NNNNNNNNNNNNNN and AI NNNNNNNNN \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA NNNNNN on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA NNNNNN on the humoral immune responses of chickens to BBBBBBBBBBBBBB and AI BBBBBBBBB \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA NNNNNN on the humoral immune responses of chickens to BBBBBBBBBBBBBB and AI BBBBBBBBB \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA NNNNNN on the humoral immune responses of chickens to BBBBBBBBBBBBBB and AI BBBBBBBBB \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA NNNNNN on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA NNNNNN on the humoral immune responses of chickens to NNNNNNNNNNNNNN and AI NNNNNNNNN \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA NNNNNN on the humoral immune responses of chickens to NNNNNNNNNNNNNN and AI NNNNNNNNN \n",
      "The objective of this study was to evaluate the effect of oral administration of AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA NNNNNN on the humoral immune responses of chickens to NNNNNNNNNNNNNN and AI NNNNNNNNN \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN AAAAAA on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN AAAAAA on the humoral immune responses of chickens to BBBBBBBBBBBBBB and AI BBBBBBBBB \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN AAAAAA on the humoral immune responses of chickens to BBBBBBBBBBBBBB and AI BBBBBBBBB \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN AAAAAA on the humoral immune responses of chickens to BBBBBBBBBBBBBB and AI BBBBBBBBB \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN AAAAAA on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN AAAAAA on the humoral immune responses of chickens to NNNNNNNNNNNNNN and AI NNNNNNNNN \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN AAAAAA on the humoral immune responses of chickens to NNNNNNNNNNNNNN and AI NNNNNNNNN \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN AAAAAA on the humoral immune responses of chickens to NNNNNNNNNNNNNN and AI NNNNNNNNN \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNN on the humoral immune responses of chickens to inactivated ND and AI vaccines. \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNN on the humoral immune responses of chickens to AAAAAAAAAAAAAA and AI AAAAAAAAA \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNN on the humoral immune responses of chickens to AAAAAAAAAAAAAA and AI AAAAAAAAA \n",
      "The objective of this study was to evaluate the effect of oral administration of NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN NNNNNN on the humoral immune responses of chickens to AAAAAAAAAAAAAA and AI AAAAAAAAA \n",
      "In experiment 2, the same regimen of AAAA was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. \n",
      "Considering the safety of GSLS, because no adverse effect was found throughout the experiments, GSLS may be a promising oral adjuvant to improve immunization in poultry.\n",
      "Interaction of AAAAAAAAAAA and imexon, in vitro and in vivo, in human A375 melanoma cells.\r\n",
      "\n",
      "We evaluated mechanisms of interaction between the alkyating agent AAAAAAAAAAA (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.\n",
      "We evaluated mechanisms of interaction between the alkyating agent AAAAAAAAAAA BBBBBB and the pro-oxidant, imexon, in the human A375 melanoma cell line.\n",
      "We evaluated mechanisms of interaction between the alkyating agent AAAAAAAAAAA (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.\n",
      "We evaluated mechanisms of interaction between the alkyating agent AAAAAAAAAAA NNNNNN and the pro-oxidant, imexon, in the human A375 melanoma cell line.\n",
      "We evaluated mechanisms of interaction between the alkyating agent NNNNNNNNNNN (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.\n",
      "We evaluated mechanisms of interaction between the alkyating agent NNNNNNNNNNN AAAAAA and the pro-oxidant, imexon, in the human A375 melanoma cell line.\n",
      "The effect of AAAA and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). \n",
      "There was a >75% reduction in cellular glutathione and cysteine with AAAAAA but not DTIC. \n",
      "AAAAAAAAA enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.\r\n",
      "\n",
      "Although it was previously reported that AAAAAAAAA combined with BBBBBBBBB improved the progression-free survival rate compared with NNNNNNNNN alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.\n",
      "Although it was previously reported that AAAAAAAAA combined with NNNNNNNNN improved the progression-free survival rate compared with BBBBBBBBB alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.\n",
      "Although it was previously reported that AAAAAAAAA combined with NNNNNNNNN improved the progression-free survival rate compared with NNNNNNNNN alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.\n",
      "Although it was previously reported that NNNNNNNNN combined with AAAAAAAAA improved the progression-free survival rate compared with BBBBBBBBB alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.\n",
      "Although it was previously reported that NNNNNNNNN combined with AAAAAAAAA improved the progression-free survival rate compared with NNNNNNNNN alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.\n",
      "Although it was previously reported that NNNNNNNNN combined with NNNNNNNNN improved the progression-free survival rate compared with AAAAAAAAA alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.\n",
      "We evaluated how AAAAAAAAA interacts with BBBBBBBBB in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). \n",
      "We evaluated how AAAAAAAAA interacts with NNNNNNNNN in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). \n",
      "We evaluated how NNNNNNNNN interacts with AAAAAAAAA in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). \n",
      "In an in vitro assay, AAAAAAAAA induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. \n",
      "AAAAAAAAA may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.\n",
      "AAAAAAAAA may have the potential to convert BBBBBBBBBBBBBBBBBBBB to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.\n",
      "AAAAAAAAA may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.\n",
      "AAAAAAAAA may have the potential to convert NNNNNNNNNNNNNNNNNNNN to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.\n",
      "NNNNNNNNN may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.\n",
      "NNNNNNNNN may have the potential to convert AAAAAAAAAAAAAAAAAAAA to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.\n",
      "The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, AAAAAAAAAAAAAAAAAAAAAAAAAAA (CRM197). \n",
      "We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of AAAAAA on these cells alone or in combination with anticancer agent. \n",
      "The purpose of this study was to evaluate whether the psychostimulant drug AAAAAAAAA has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.\n",
      "In the hot plate test in mice, co-administration of 15     g/kg AAAAAAAAAAAAAAA with 10   mg/kg BBBBBBBBB intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. \n",
      "In the hot plate test in mice, co-administration of 15     g/kg AAAAAAAAAAAAAAA with 10   mg/kg NNNNNNNNN intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. \n",
      "In the hot plate test in mice, co-administration of 15     g/kg NNNNNNNNNNNNNNN with 10   mg/kg AAAAAAAAA intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. \n",
      "At the same time, the locomotor inhibitory effect of AAAAAAAAAAAAAAA was counteracted by ephedrine. \n",
      "[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease]\n",
      "[Efficacy of fixed combination AAAAAAAAAAAAAAAAAAAA in hospitalized patients with hypertensive disease]\n",
      "Efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. \n",
      "Efficacy and tolerability of fixed AAAAAAAAAAAAAAAAAAAA combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. \n",
      "All patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43). \n",
      "All patients had indications for antihypertensive therapy and were randomized either to fixed combination AAAAAAAAAAAAAAAAAAAA (n=43) or to therapy which corresponded to the hospital formulary (n=43). \n",
      "Rate of achievement of target BP with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%). \n",
      "Rate of achievement of target BP with fixed combination AAAAAAAAAAAAAAAAAAAA (93%) was comparable with that on traditional therapy (90%). \n",
      "But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). \n",
      "But the use of fixed combination AAAAAAAAAAAAAAAAAAAA compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). \n",
      "But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). \n",
      "But the use of fixed combination AAAAAAAAAAAAAAAAAAAA compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). \n",
      "But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). \n",
      "But the use of fixed combination NNNNNNNNNNNNNNNNNNNN compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). \n",
      "We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.\n",
      "We have demonstrated appropriateness of inhospital administration of fixed AAAAAAAAAAAAAAAAAAAA combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.\n",
      "We have demonstrated appropriateness of inhospital administration of fixed BBBBBBBBBBBBBBBBBBBB combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.\n",
      "We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.\n",
      "We have demonstrated appropriateness of inhospital administration of fixed AAAAAAAAAAAAAAAAAAAA combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.\n",
      "We have demonstrated appropriateness of inhospital administration of fixed NNNNNNNNNNNNNNNNNNNN combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.\n",
      "We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.\n",
      "We have demonstrated appropriateness of inhospital administration of fixed NNNNNNNNNNNNNNNNNNNN combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.\n",
      "We have demonstrated appropriateness of inhospital administration of fixed AAAAAAAAAAAAAAAAAAAA combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.\n",
      "AAAAAAAAAA (Brilinta)--better than clopidogrel (Plavix)\n",
      "AAAAAAAAAA BBBBBBBBBBBBBBBBBB than NNNNNNNNNNN (Plavix)\n",
      "AAAAAAAAAA (Brilinta)--better than clopidogrel (Plavix)\n",
      "AAAAAAAAAA NNNNNNNNNNNNNNNNNN than BBBBBBBBBBB (Plavix)\n",
      "AAAAAAAAAA (Brilinta)--better than clopidogrel (Plavix)\n",
      "AAAAAAAAAA NNNNNNNNNNNNNNNNNN than NNNNNNNNNNN (Plavix)\n",
      "NNNNNNNNNN (Brilinta)--better than clopidogrel (Plavix)\n",
      "NNNNNNNNNN AAAAAAAAAAAAAAAAAA than BBBBBBBBBBB (Plavix)\n",
      "NNNNNNNNNN (Brilinta)--better than clopidogrel (Plavix)\n",
      "NNNNNNNNNN AAAAAAAAAAAAAAAAAA than NNNNNNNNNNN (Plavix)\n",
      "NNNNNNNNNN (Brilinta)--better than clopidogrel (Plavix)\n",
      "NNNNNNNNNN NNNNNNNNNNNNNNNNNN than AAAAAAAAAAA (Plavix)\n",
      "The FDA has approved AAAAAAAAAA (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved AAAAAAAAAA BBBBBBBBBBBBBBBBBBBBBBB an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved AAAAAAAAAA (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved AAAAAAAAAA NNNNNNNNNNNNNNNNNNNNNNN an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved AAAAAAAAAA (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved AAAAAAAAAA NNNNNNNNNNNNNNNNNNNNNNN an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved NNNNNNNNNN (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved NNNNNNNNNN AAAAAAAAAAAAAAAAAAAAAAA an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved NNNNNNNNNN (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved NNNNNNNNNN AAAAAAAAAAAAAAAAAAAAAAA an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved NNNNNNNNNN (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "The FDA has approved NNNNNNNNNN NNNNNNNNNNNNNNNNNNNNNNN an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). \n",
      "It will compete with AAAAAAAAAAA (Plavix) and prasugrel (Effient) for such use. \n",
      "It will compete with AAAAAAAAAAA BBBBBBBB and NNNNNNNNN (Effient) for such use. \n",
      "It will compete with AAAAAAAAAAA (Plavix) and prasugrel (Effient) for such use. \n",
      "It will compete with AAAAAAAAAAA NNNNNNNN and BBBBBBBBB (Effient) for such use. \n",
      "It will compete with AAAAAAAAAAA (Plavix) and prasugrel (Effient) for such use. \n",
      "It will compete with AAAAAAAAAAA NNNNNNNN and NNNNNNNNN (Effient) for such use. \n",
      "It will compete with NNNNNNNNNNN (Plavix) and prasugrel (Effient) for such use. \n",
      "It will compete with NNNNNNNNNNN AAAAAAAA and BBBBBBBBB (Effient) for such use. \n",
      "It will compete with NNNNNNNNNNN (Plavix) and prasugrel (Effient) for such use. \n",
      "It will compete with NNNNNNNNNNN AAAAAAAA and NNNNNNNNN (Effient) for such use. \n",
      "It will compete with NNNNNNNNNNN (Plavix) and prasugrel (Effient) for such use. \n",
      "It will compete with NNNNNNNNNNN NNNNNNNN and AAAAAAAAA (Effient) for such use. \n",
      "Evaluation of antidepressant like activity of AAAAAAAA and its combination with BBBBBBBBBB and imipramine: an acute and chronic study.\r\n",
      "\n",
      "Evaluation of antidepressant like activity of AAAAAAAA and its combination with NNNNNNNNNN and imipramine: an acute and chronic study.\r\n",
      "\n",
      "Evaluation of antidepressant like activity of NNNNNNNN and its combination with AAAAAAAAAA and imipramine: an acute and chronic study.\r\n",
      "\n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 BBBBBBBBB 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 BBBBBBBBB 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 BBBBBBBBB 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 BBBBBBBBB 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 BBBBBBBBBBB 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 BBBBBBBBBBB 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 BBBBBBBBBBB 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 BBBBBBBBBBB 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 BBBBBBBBBBB 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 BBBBBBBBB 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus BBBBBBBBBB 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 AAAAAAAAA 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 BBBBBBBBBBB 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 BBBBBBBBBBB 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 BBBBBBBBBBB 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 BBBBBBBBBBB 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 BBBBBBBBBBB 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 BBBBBBBBB 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus BBBBBBBBBB 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 AAAAAAAAA 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 BBBBBBBBBBB 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 BBBBBBBBBBB 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 BBBBBBBBB 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus BBBBBBBBBB 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 AAAAAAAAAAA 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 AAAAAAAAAAA 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 AAAAAAAAAAA 15 mg/kg), group 6 BBBBBBBBB 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 AAAAAAAAAAA 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 AAAAAAAAAAA 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus BBBBBBBBBB 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 AAAAAAAAAAA 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 AAAAAAAAAAA 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 AAAAAAAAAAA 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 AAAAAAAAAAA 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 AAAAAAAAA 100 mg/kg plus BBBBBBBBBB 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 AAAAAAAAA 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 AAAAAAAAA 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus AAAAAAAAAA 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus AAAAAAAAAA 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 NNNNNNNNN 50 mg/kg), group 3 NNNNNNNNN 100 mg/kg), group 4 NNNNNNNNNNN 20 mg/kg), group 5 NNNNNNNNNNN 15 mg/kg), group 6 NNNNNNNNN 100 mg/kg plus NNNNNNNNNN 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg). \n",
      "In the present study AAAAAAAA (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of BBBBBBBBB evaluated by both NNNNNNNNNNN writhing and formalin test, when it was administered with ibuprofen. \n",
      "In the present study AAAAAAAA (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of NNNNNNNNN evaluated by both BBBBBBBBBBB writhing and formalin test, when it was administered with ibuprofen. \n",
      "In the present study AAAAAAAA (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of NNNNNNNNN evaluated by both NNNNNNNNNNN writhing and formalin test, when it was administered with ibuprofen. \n",
      "In the present study NNNNNNNN (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of AAAAAAAAA evaluated by both BBBBBBBBBBB writhing and formalin test, when it was administered with ibuprofen. \n",
      "In the present study NNNNNNNN (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of AAAAAAAAA evaluated by both NNNNNNNNNNN writhing and formalin test, when it was administered with ibuprofen. \n",
      "In the present study NNNNNNNN (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of NNNNNNNNN evaluated by both AAAAAAAAAAA writhing and formalin test, when it was administered with ibuprofen. \n",
      "AAAAAAAAA plasma concentration was also increased when it was administered with piperine. \n",
      "The synergistic antinociception activity of AAAAAAAAA when administered with BBBBBBBB can be attributed to increased plasma concentration of ibuprofen. \n",
      "The synergistic antinociception activity of AAAAAAAAA when administered with NNNNNNNN can be attributed to increased plasma concentration of ibuprofen. \n",
      "The synergistic antinociception activity of NNNNNNNNN when administered with AAAAAAAA can be attributed to increased plasma concentration of ibuprofen. \n",
      "From this study it can be concluded that AAAAAAAA can be used as a bioenhancer along with ibuprofen.\n"
     ]
    }
   ],
   "source": [
    "#file_path = \"Train/MedLine/\"\n",
    "file_path = \"Test/Test_data_DDI/MedLine\"\n",
    "files = os.listdir(file_path)\n",
    "idd = 5265\n",
    "for file in files:\n",
    "    path = os.path.join(file_path,file)\n",
    "    tree = read_xml(path)\n",
    "    idd = create_dict(tree.getroot(),idd)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "invalid syntax (<ipython-input-76-9d09c83bef11>, line 1)",
     "output_type": "error",
     "traceback": [
      "\u001b[1;36m  File \u001b[1;32m\"<ipython-input-76-9d09c83bef11>\"\u001b[1;36m, line \u001b[1;32m1\u001b[0m\n\u001b[1;33m    def go_through_file:\u001b[0m\n\u001b[1;37m                       ^\u001b[0m\n\u001b[1;31mSyntaxError\u001b[0m\u001b[1;31m:\u001b[0m invalid syntax\n"
     ]
    }
   ],
   "source": [
    "def go_through_file:\n",
    "    files = os.listdir(filepath)\n",
    "      for fi in files:\n",
    "        fi_d = os.path.join(filepath,fi)            \n",
    "        if os.path.isdir(fi_d):\n",
    "          gci(fi_d)                  \n",
    "        else:\n",
    "          print os.path.join(filepath,fi_d)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(whole_num)\n",
    "global whole_num = 0"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
